Bronchogenic Carcinoma — Trials

Bronchogenic Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

35 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Nanfang Hospital, Southern Medical University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03037385	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW)	completed	Phase 1 / Phase 2	590	Hoffmann-La RocheINDUSTRY	13	May 31, 2025	clinicaltrials
NCT00102505	A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)	completed	Phase 1	36	Pharmacyclics LLC.INDUSTRY	1